CRISPR/Cas9 for achieving postintervention HIV control.

Area of Science:

• Biotechnology
• Gene Therapy
• Immunology

Background:

• CRISPR/Cas9 technology has advanced, leading to approved therapies for genetic disorders.
• Gene therapy offers potential for targeting HIV persistence and achieving long-term control after treatment.

Purpose of the Study:

• To review recent updates in CRISPR/Cas9-based gene therapy for human immunodeficiency virus (HIV).
• To discuss strategies including CCR5-editing, proviral targeting, and immune cell engineering.

Main Methods:

• Review of recent studies on CRISPR/Cas9 gene therapy for HIV.
• Analysis of ex vivo and in vivo editing approaches.
• Evaluation of novel delivery methods like lipid nanoparticles.

Main Results:

• CRISPR/Cas9 gene therapies show safety data but require improved in vivo editing efficiency.
• Challenges include efficient delivery for proviral excision and engraftment/durability for ex vivo editing.
• Combination gene therapy approaches demonstrate proof-of-concept for HIV control.

Conclusions:

• Gene therapy approaches are feasible for achieving post-intervention HIV control.
• Enhancements in both ex vivo and in vivo delivery methods are necessary for clinical translation.